Fig. 7
The therapeutic effects of LAG3 inhibitors and monoclonal antibodies on SKCM in mice. (A) Changes in body weight and tumor volume of mice during the modeling process; (B) changes in tumor volume of mice in different treatment groups, at which time D0 is the 11th day of drug administration treatment; (C) changes in body weight of mice in different treatment groups, at which time D0 is the 11th day of drug administration treatment; (D) tumor sizes and weights in different treatment groups; (E) Tumor weight of mice in different treatment groups; (F) tumor metastasis in vivo in different treatment groups; (G) HE staining demonstrated immune cell infiltration in each group; (H) Ki67 immunohistochemistry detected tumor proliferation in mice, the scale was set to 10 μm; (I) Ki67 quantified histogram of tumor proliferation in mice in each treatment group; (J) IHC histogram of LAG3, CTLA-4 and CD8 in each treatment group; (K) The expressions of LAG3, CTLA-4 and CD8 in each treatment group were detected by IHC, the scale was set to 20 μm. “*” indicated the significant P value of the DMSO and Miptenalimab groups, with * representing P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001; and “#” indicated the significant P value of the DMSO and ZYF0033 groups, with # representing P < 0.05, ## P < 0.01, and #### P < 0.001.
